ClinicalTrials.gg
CompletedNCT07592377Updated Oct 1, 2026

Multicenter Study on the Use of a Collagen-based Hydrogel for the Treatment of 153 Periodontal Pockets in 38 Adults With Generalized Stage III Periodontitis

An observational study in Periodontal Pocket and Periodontitis, sponsored by Bioteck S.p.A.. Completed at 2 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bioteck S.p.A. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
38
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Periodontal Pocket with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Periodontal Pocket · Italy.

Started
2024
with 3 others
Observational
3 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Bioteck S.p.A.

Among the 20 studies in Periodontal Pocket with a site in Italy, this one is one of 4 that started in 2024, is one of 3 observational ones, and was the 19th registered.

Periodontal Pocket

130 studies on the registry are indexed under Periodontal Pocket; 35 are open to participants now.

Browse Periodontal Pocket studies →

Open to participants now

5 of the 20 studies in Periodontal Pocket with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 23 Periodontal Pocket studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 3 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Periodontal Pocket with a site in Italy, or all of them as a file.
02

Study summary

This is a prospective, observational, multicenter study designed to evaluate the real-world efficacy and safety of H42®, a collagen hydrogel, in the treatment of periodontal pockets. The study will include 153 observations related to 38 subjects (aged 18-65) undergoing periodontal treatment in routine clinical practice. H42® is intended for filling, reinforcing, and repairing periodontal pockets.

The primary objective is to evaluate the change in Periodontal Pocket Depth (PPD) from baseline to week 12.

Secondary objectives include assessing:

  • Clinical Attachment Level (CAL): Calculated as PPD minus the distance from the cemento-enamel junction (CEJ) to the free gingival margin (FGM).
  • Inflammatory Indices: Sulcus Bleeding Index (SBI), Bleeding On Probing (BOP), and Gingival Index (GI).
  • Plaque Control: Plaque Index (PI) using the Silness and Löe scale.
  • Patient-Reported Outcomes: Pain levels via a Numeric Rating Scale (NRS 0-10) and treatment satisfaction.
  • Safety: Clinical assessment of infection (suppuration), Global Safety assessed by the Investigator (IGAS), and Global Safety assessed by the Patient (PGAS).

Participants undergo a baseline visit (V1) and six follow-up visits (V2-V7) over 12 weeks:

  • V1 (Baseline): Mechanical instrumentation (scaling and root planing) followed by the application of H42® hydrogel (up to 5 pockets per patient). Baseline assessments include PPD, CAL, SBI, BOP, PI, GI, NRS pain, and radiographic imaging (X-ray or CBCT).
  • V2, V3, V4 (Weeks 1, 2, 3): Evaluation of GI, pain (NRS), and presence of infection/suppuration.
  • V5 (Week 4) \& V6 (Week 8): Comprehensive periodontal assessment including PPD, CAL, SBI, BOP, PI, GI, and pain monitoring.
  • V7 (Week 12 - End of Study): Final assessment of all periodontal parameters, radiographic imaging to measure pocket depth reduction, patient satisfaction survey, and global safety assessments (IGAS/PGAS).

Clinical photography is used throughout the study to support the evaluation of gingival inflammatory status.

03

Conditions studied

  • Periodontal Pocket
  • Periodontitis

Keywords

  • Dental Scaling
  • Root Planing
  • Hydrogels
  • Collagen
  • Biocompatible Materials
  • Wound Healing
  • Inflammation
  • Prospective Studies
  • Multicenter Study
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The dataset includes 153 observations related to 38 subjects, with multiple observations per subject due to different tooth positions. The study was conducted in two dental clinics located in Italy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women with age between 18 and 65 years.
  • Stage 3 generalized periodontitis
  • Subjects affected by periodontal pockets with probing depth (PD) in the range between 5 to 8 mm
  • For each subject a maximum of 5 defects were evaluated. If the patient presented more defects, at the beginning of the study the investigator identified the "target" lesions.
  • Subjects who followed in the previous two weeks instructions to oral hygiene (proper brushing techniques twice a day, proper flossing technique daily).
  • Subjects able to communicate adequately with the Investigator and to comply with the requirements for the entire study.
  • The decision to prescribe H42® as an adjunctive therapy for the condition was entirely independent of that of including the patient in the study.
  • Subjects or legal representatives had to be willing and able to give /assent for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects presenting current or previous bleeding disorders.
  • Subjects taking or having indications for anticoagulant therapy.
  • Use of aspirin and antiplatelet agents within one week prior to treatment.
  • Subjects with history of allergy or to the tested device or to its ingredients, or hypersensitivity skin reaction to the device, or at risk in term of precautions, warnings and referred in the package insert of the clinical investigation device.
  • Use of concomitant treatments or procedures aimed to improve gums health over the last six months before the clinical investigation enrolment, such as HA gel treatments, injection of fillers, surgery.
  • Subjects unlikely to cooperate in the clinical investigation or with the clinical investigation visits.
  • Pregnant or lactating women, or women of planning a pregnancy during the study.
  • Subjects with illness, or other medical condition that, in the opinion of the investigator, would have compromised participation, or that would likely have resulted in hospitalization during the study (e.g., epilepsy), or predisposed to infections (e.g. infection, acute hepatitis), or jeopardized the evaluation of the study results (e.g. herpes virus infection).
  • Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days.
  • Any reason, according to Investigator's judgement, able to compromise compliance with procedures outlined in the study protocol or making participation in the study not advisable, was considered.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
38 participants (actual)
Target follow-up
12 Weeks
Patient registry
Yes

Interventions

  • DeviceH42® Collagen Hydrogel for the non-surgical treatment of periodontal pockets

    Application of H42® collagen hydrogel for filling, reinforcing, and repairing periodontal pockets. Following standard mechanical instrumentation (scaling and root planing), the hydrogel is applied to a maximum of 5 periodontal pockets per patient (153 total pockets). The treatment is part of routine clinical practice to evaluate its real-world efficacy and safety over a 12-week period.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Periodontal Pocket Depth (PPD) at 12 weeks following application of H42® hydrogel in 153 periodontal pockets

    Evaluation of the reduction in PPD, measured in millimeters (mm), from baseline to week 12. The H42® collagen hydrogel is applied to 153 periodontal pockets immediately following mechanical instrumentation for the removal of biofilm and mineralized deposits. The change is calculated as the difference between the measurement at the 12-week follow-up and the baseline value recorded.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks

Secondary outcomes

  1. Change from Baseline in Clinical Attachment Level (CAL) at Weeks 4, 8, and 12

    CAL will be evaluated to assess periodontal tissue regeneration. Measurement is calculated using the formula: CAL = PPD - (CEJ to FGM distance), where PPD is Probing Pocket Depth, CEJ is Cemento-Enamel Junction, and FGM is Free Gingival Margin. Measurements will be taken in millimeters (mm).

    Time frame: Baseline, Week 4, Week 8, Week 12

  2. Change from Baseline in Sulcus Bleeding Index (SBI) at Weeks 4, 8, and 12

    SBI will be used to assess gingival inflammation. Scoring is based on Mühlemann and Son (1971) criteria on a scale from 0 to 5, where: 0 = normal texture and color, no bleeding; 1 = apparently normal, bleeding on probing; 2 = bleeding on probing, color change, no edema; 3 = bleeding on probing, color change, slight edema; 4 = bleeding on probing, color change, obvious edema (or bleeding on probing and obvious edema); 5 = bleeding on probing, spontaneous bleeding, color change, and marked edema. Higher scores indicate greater inflammation.

    Time frame: Baseline, Week 4, Week 8, Week 12

  3. Change from Baseline in Percentage of Bleeding on Probing (BOP) sites at Weeks 4, 8, and 12

    BOP will be assessed to evaluate the extent of periodontal inflammation. Bleeding will be recorded as present (1) or absent (0) within 15 seconds following pocket probing. The Full-Mouth Bleeding Score (FMBS) will be calculated as a percentage using the formula: (number of bleeding sites / total number of evaluated sites) x 100. Values range from 0% to 100%, with lower percentages indicating better periodontal health.

    Time frame: Baseline, Week 4, Week 8, Week 12

  4. Change from Baseline in Plaque Index (PI) at Weeks 4, 8, and 12

    PI will be used to evaluate the presence and thickness of plaque at the gingival margin. Scoring is based on the Silness and Löe Plaque Index criteria on a scale from 0 to 3, where: 0 = no plaque; 1 = a film of plaque adhering to the free gingival margin and adjacent area of the tooth, recognized only by running a probe across the tooth surface; 2 = moderate accumulation of soft deposits within the gingival pocket, or on the tooth and gingival margin, visible to the naked eye; 3 = abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin. Higher scores indicate greater plaque accumulation. The final value represents the patient's average score across all examined surfaces.

    Time frame: Baseline, Week 4, Week 8, Week 12

  5. Change from Baseline in Gingival Index (GI) at Weeks 1, 2, 3, 4, and 12

    GI will be assessed to evaluate the severity and qualitative changes of gingival inflammation. Scoring is based on the Löe and Silness Gingival Index criteria on a 4-point scale from 0 to 3, where: 0 = normal gingiva; 1 = mild inflammation, slight change in color, slight edema, no bleeding on probing; 2 = moderate inflammation, redness, edema, and glazing, bleeding on probing; 3 = severe inflammation, marked redness and edema, ulceration, tendency to spontaneous bleeding. Higher scores indicate more severe gingival inflammation.

    Time frame: Baseline, Weeks 1, Weeks 2, Week 4, Week 8, Week 12

  6. Change from Baseline in Patient-Reported Pain Score at Weeks 1, 2, 4, 8, and 12

    Patient-reported pain will be assessed using an 11-point Numeric Rating Scale (NRS). The scale ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "the worst possible pain". Higher scores represent greater pain intensity.

    Time frame: Baseline, Weeks 1, Weeks 2, Week 4, Week 8, Week 12

  7. Investigator Global Assessment of Performance (IGAP) at Week 12

    Global Performance of the tested device as assessed by the Investigator (IGAP) through visual evaluation of standardized photographs taken during clinical visits. The evaluation is rated using a 4-point Likert scale: 1 = very good performance; 2 = good performance; 3 = moderate performance; 4 = poor performance. Higher scores indicate worse performance or lower efficacy of the tested device.

    Time frame: Week 12

  8. Patient Degree of Satisfaction at Week 12

    Patient self-reported degree of satisfaction with the treatment/device, evaluated through a 4-point satisfaction scale. The response options are defined as follows: 1 = very satisfied; 2 = satisfied; 3 = moderately satisfied; 4 = not satisfied. Higher scores indicate lower patient satisfaction.

    Time frame: Week 12

  9. Change from Baseline in radiographic Periodontal Pocket Depth at Week 12

    Radiographic evaluation to assess the change from baseline to Week 12 in parameters related to the periodontal pocket depth. Measurements will be performed on standardized intraoral radiographs to quantify the vertical bone loss or defect associated with the pocket.

    Time frame: Baseline, Week 12

  10. Percentage of participants with absence of infection (Suppuration) from Week 1 to Week 12

    Clinical evaluation to assess the absence of infection, specifically defined as the absence of suppuration (pus formation), at the treated site as evaluated by the Investigator. The presence or absence of suppuration will be assessed at each post-baseline visit. Results will be expressed as the percentage of participants achieving complete absence of suppuration compared to baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, and Week 12

07

Study locations

2 sites
  • Studio Brecodent
    Dongo, Como 22014, Italy
  • Studio Parma Benfenati
    Ferrara, Ferrara 44121, Italy
08

References and documents

Publications

  • Schwartz, G. Estimating the Dimension of the Model. Ann Sturist 1978; 6:461-464.
  • Akaike, H. A Bayesian Analysis of the Minimum AIC Procedure. Ann Insr Stutisr Murh Part A 1978; 30: Q-14.
  • Periodontology, A. A. P. (2001). Glossary of periodontal terms. Chicago (IL): The American Academy of Periodontology.
  • Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley & Sons. DOI:10.1002/0470092602
  • Chung HM, Park JY, Ko KA, Kim CS, Choi SH, Lee JS. Periodontal probing on digital images compared to clinical measurements in periodontitis patients. Sci Rep. 2022 Jan 31;12(1):1616. doi: 10.1038/s41598-021-04695-6. PubMed 35102150 ↗
  • Levrini L, Paracchini L, Nosotti MG. The Capacity of Periodontal Gel to Occupy the Spaces Inside the Periodontal Pockets Using Computational Fluid Dynamic. Dent J (Basel). 2019 Dec 24;8(1):1. doi: 10.3390/dj8010001. PubMed 31878278 ↗
  • LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available. PubMed 14121956 ↗
  • SILNESS J, LOE H. PERIODONTAL DISEASE IN PREGNANCY. II. CORRELATION BETWEEN ORAL HYGIENE AND PERIODONTAL CONDTION. Acta Odontol Scand. 1964 Feb;22:121-35. doi: 10.3109/00016356408993968. No abstract available. PubMed 14158464 ↗
  • Muhlemann HR, Son S. Gingival sulcus bleeding--a leading symptom in initial gingivitis. Helv Odontol Acta. 1971 Oct;15(2):107-13. No abstract available. PubMed 5315729 ↗
  • Barbosa VL, Angst PD, Finger Stadler A, Oppermann RV, Gomes SC. Clinical attachment loss: estimation by direct and indirect methods. Int Dent J. 2016 Jun;66(3):144-9. doi: 10.1111/idj.12218. Epub 2016 Feb 5. PubMed 26846817 ↗
  • Jepsen S, Caton JG, Albandar JM, Bissada NF, Bouchard P, Cortellini P, Demirel K, de Sanctis M, Ercoli C, Fan J, Geurs NC, Hughes FJ, Jin L, Kantarci A, Lalla E, Madianos PN, Matthews D, McGuire MK, Mills MP, Preshaw PM, Reynolds MA, Sculean A, Susin C, West NX, Yamazaki K. Periodontal manifestations of systemic diseases and developmental and acquired conditions: Consensus report of workgroup 3 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S237-S248. doi: 10.1002/JPER.17-0733. PubMed 29926943 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Dec 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 18, 2026
StartActual
Feb 12, 2024
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 20, 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07592377
Lead sponsor
Bioteck S.p.A.
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Feb 12, 2024
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Oct 1, 2026

Study contacts

Marisa Roncati, Dental Degree
principal investigator · Studio Parma Benfenati Corso della Giovecca 155/a 44121 - Ferrara (Italy)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion